Insider · CIK 0001824862
Kenneth Carl Anderson
director
Files at CCCC (C4 Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | CCCC C4 Therapeutics, Inc. | AGrant or award Common Stock | +3,662 | $3.14 | $11k | 75,612 | 10 d ago |
| Jul 1, 2025 | CCCC C4 Therapeutics, Inc. | AGrant or award Common Stock | +7,616 | $1.51 | $12k | 135,225 | Jul 2, 2025 |
| Jun 18, 2025 | CCCC C4 Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +35,500 | $0.00 | $0 | 35,500 | Jun 20, 2025 |
| Apr 1, 2025 | CCCC C4 Therapeutics, Inc. | AGrant or award Common Stock | +7,841 | $1.44 | $11k | 127,609 | Apr 3, 2025 |
| Jan 2, 2025 | CCCC C4 Therapeutics, Inc. | AGrant or award Common Stock | +3,074 | $3.66 | $11k | 119,768 | Jan 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.